AVXL

MKT CAP:$311M

Anavex Life Sciences Corp.

Market Cap

$311M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.31-$0.37 (-10.05%)

Apr 23, 2026

Company Details

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III ...

CEO

Christopher U. Missling

IPO Date

Aug 2, 2006

Website

www.anavex.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$40M

EPS (Diluted)

-$0.46

Free Cash Flow

-$34M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q2 2026

May 12, 2026

PENDING

Q1 2026

Feb 9, 2026

$0EPS -$0.06

FY 2025

Nov 25, 2025

$0EPS -$0.54

Q4 2025

Nov 25, 2025

$0EPS -$0.11

Q3 2025

Aug 12, 2025

$0EPS -$0.16

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q2 22	$0	$0	-$12M
Q3 22	$0	$0	-$12M
Q4 22	$0	$0	-$15M
Q1 23	$0	$0	-$15M
Q2 23	$0	$0	-$14M
Q3 23	$0	$0	-$14M
Q4 23	$0	$0	-$13M
Q1 24	$0	$0	-$11M
Q2 24	$0	$0	-$13M
Q3 24	$0	$0	-$15M
Q4 24	$0	$0	-$14M
Q1 25	$0	$0	-$14M
Q2 25	$0	$0	-$13M
Q3 25	$0	$0	-$14M
Q4 25	$0	$0	-$11M
Q1 26	$0	$0	-$7M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q2 22	-$10M	-$10M
Q3 22	-$7M	-$7M
Q4 22	-$4M	-$4M
Q1 23	-$6M	-$6M
Q2 23	-$8M	-$8M
Q3 23	-$8M	-$8M
Q4 23	-$6M	-$6M
Q1 24	-$7M	-$7M
Q2 24	-$12M	-$12M
Q3 24	-$5M	-$5M
Q4 24	-$7M	-$7M
Q1 25	-$12M	-$12M
Q2 25	-$6M	-$6M
Q3 25	-$12M	-$12M
Q4 25	-$9M	-$9M
Q1 26	-$7M	-$7M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q2 22	—	+28.8%
Q3 22	—	+9.7%
Q4 22	—	+24.7%
Q1 23	—	+31.0%
Q2 23	—	+23.2%
Q3 23	—	+8.6%
Q4 23	—	-17.2%
Q1 24	—	-25.9%
Q2 24	—	-11.0%
Q3 24	—	+7.9%
Q4 24	—	+13.3%
Q1 25	—	+19.5%
Q2 25	—	-0.9%
Q3 25	—	-1.0%
Q4 25	—	-24.4%
Q1 26	—	-50.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q2 22	$4M	—
Q3 22	$4M	—
Q4 22	$6M	—
Q1 23	$5M	—
Q2 23	$4M	—
Q3 23	$4M	—
Q4 23	$3M	—
Q1 24	$2M	—
Q2 24	$3M	—
Q3 24	$2M	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$1M	—
Q3 25	$4M	—
Q4 25	$4M	—
Q1 26	$1M	—

OpEx Breakdown

Quarter	R&D	G&A
Q2 22	$9M	$3M
Q3 22	$9M	$3M
Q4 22	$11M	$4M
Q1 23	$12M	$3M
Q2 23	$11M	$3M
Q3 23	$10M	$3M
Q4 23	$10M	$3M
Q1 24	$9M	$3M
Q2 24	$10M	$3M
Q3 24	$12M	$3M
Q4 24	$12M	$3M
Q1 25	$10M	$3M
Q2 25	$10M	$3M
Q3 25	$10M	$5M
Q4 25	$7M	$4M
Q1 26	$5M	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q2 22	$153M	$0	$153M
Q3 22	$153M	$0	$153M
Q4 22	$149M	$0	$149M
Q1 23	$144M	$0	$144M
Q2 23	$153M	$0	$153M
Q3 23	$155M	$0	$155M
Q4 23	$151M	$0	$151M
Q1 24	$144M	$0	$144M
Q2 24	$139M	$0	$139M
Q3 24	$139M	$0	$139M
Q4 24	$132M	$0	$132M
Q1 25	$121M	$0	$121M
Q2 25	$116M	$0	$116M
Q3 25	$101M	$0	$101M
Q4 25	$103M	$0	$103M
Q1 26	$132M	$0	$132M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q2 22	76M	+0.3%	+11.2%
Q3 22	77M	+1.6%	+9.7%
Q4 22	77M	-0.7%	+1.2%
Q1 23	78M	+1.4%	+2.6%
Q2 23	78M	+0.4%	+2.7%
Q3 23	81M	+3.3%	+4.4%
Q4 23	80M	-1.3%	+3.7%
Q1 24	82M	+2.9%	+5.3%
Q2 24	82M	+0.5%	+5.3%
Q3 24	85M	+2.5%	+4.5%
Q4 24	84M	-0.6%	+5.3%
Q1 25	85M	+1.0%	+3.3%
Q2 25	85M	+0.3%	+3.2%
Q3 25	85M	+0.4%	+1.0%
Q4 25	86M	+0.6%	+2.3%
Q1 26	89M	+3.7%	+5.0%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q2 22	$0	25
Q3 22	$0	25
Q4 22	$0	38
Q1 23	$0	38
Q2 23	$0	38
Q3 23	$0	38
Q4 23	$0	40
Q1 24	$0	40
Q2 24	$0	40
Q3 24	$0	40
Q4 24	$0	42
Q1 25	$0	42
Q2 25	$0	42
Q3 25	$0	42
Q4 25	$0	34
Q1 26	$0	34

Revenue / Employee